newsfilter
← Latest News
PR Newswire·

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

Patient dosing initiated for Phase 2b study of PUR1900 for ABPA Phase 1 study of PUR3100 for migraine achieves positive topline results $30.8 million in cash and cash equivalents at the end of Q1 2023 providing projected